Search

Your search keyword '"Dahan, Laetitia"' showing total 354 results
Start Over Author "Dahan, Laetitia"
354 results on '"Dahan, Laetitia"'

1. Neoadjuvant radiotherapy combined with fluorouracil-cisplatin plus cetuximab in operable, locally advanced esophageal carcinoma: Results of a phase I-II trial (FFCD-0505/PRODIGE-3)

Author

de Rauglaudre, Bernadette, Piessen, Guillaume, Jary, Marine, Le Malicot, Karine, Adenis, Antoine, Mazard, Thibault, D’Journo, Xavier Benoît, Petorin, Caroline, Buffet-Miny, Joelle, Aparicio, Thomas, Guimbaud, Rosine, Vendrely, Véronique, Lepage, Côme, and Dahan, Laetitia

Published
2024
Full Text
View/download PDF

2. Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study

Author

Kim, Stefano, Ghiringhelli, Francois, de la Fouchardière, Christelle, Evesque, Ludovic, Smith, Denis, Badet, Nicolas, Samalin, Emmanuelle, Lopez-Trabada Ataz, Daniel, Parzy, Aurelie, Desramé, Jérôme, Baba Hamed, Nabil, Buecher, Bruno, Tougeron, David, Bouché, Olivier, Dahan, Laetitia, Chibaudel, Benoist, El Hajbi, Farid, Mineur, Laurent, Dubreuil, Olivier, Ben Abdelghani, Meher, Pecout, Solange, Bibeau, Frederic, Herfs, Michael, Garcia, Marie-Line, Meurisse, Aurelia, Vernerey, Dewi, Taïeb, Julien, and Borg, Christophe

Published
2024
Full Text
View/download PDF

3. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

Author

Abou-Alfa, Ghassan, Alfonso, Jorge Adeva, Aglietta, Massimo, Baron, Ari, Beg, Muhammad, Aguirre, Paula Carrasco, Chen, Eric, Cheng, Ying, Gracián, Antonio Cubillo, Dahan, Laetitia, De Braud, Filippo, Fenocchio, Elisabetta, Gbolohon, Olumide, Gillmore, Roopinder, Jary, Marine, Javle, Milind, Jiang, Yixing, Kang, Jung Hun, King, Gentry George, Kundranda, Madappa, Layos, Laura, Li, Daneng, Liang, Tingbo, Lonardi, Sara, Marathe, Omkar, Mondaca, Sebastian, Martin, Andrés J. Muñoz, Park, Joon Oh, Pazo Cid, Roberto, Fernandez, Paula Ribera, Rimassa, Lorenza, Alonso, Rosa Rodriguez, Sadeghi, Saeed, Scott, Aaron, Tan, Benjamin, Tougeron, David, Yan, Qiang, Yin, Xiaoyu, Zhao, Haitao, Harding, James J, Fan, Jia, Oh, Do-Youn, Choi, Hye Jin, Kim, Jin Won, Chang, Heung-Moon, Bao, Lequn, Sun, Hui-Chuan, Macarulla, Teresa, Xie, Feng, Metges, Jean-Phillippe, Ying, Jie'er, Bridgewater, John, Lee, Myung-Ah, Tejani, Mohamedtaki A, Chen, Emerson Y, Kim, Dong Uk, Wasan, Harpreet, Ducreux, Michel, Bao, Yuanyuan, Boyken, Lisa, Ma, Jiafang, Garfin, Phillip, and Pant, Shubham

Published
2023
Full Text
View/download PDF

5. Acceptance, efficacy, and safety of COVID-19 vaccination in older patients with cancer

Author

Couderc, Anne-Laure, Ninove, Laetitia, Nouguerède, Emilie, Rey, Dominique, Rebroin, Marina, Daumas, Aurélie, Tomasini, Pascale, Greillier, Laurent, Salas, Sebastien, Duffaud, Florence, Dahan, Laetitia, Duluc, Muriel, Garcia, Marie-Eve, Pluvy, Johan, Chaléat, Solène, Farnault, Laure, Venton, Geoffroy, Fourié, Toscane, Nurtop, Elif, de Lamballerie, Xavier, Villani, Patrick, Charrel, Remi, and Correard, Florian

Published
2022
Full Text
View/download PDF

7. Maintenance therapy with olaparib or selumetinib plus durvalumab (S+D) according to genetic profile of metastatic pancreatic adenocarcinoma (m-PDAC) controlled with modified FOLFIRINOX (mFFX): A phase II randomized MAZEPPA GERCOR D19-02 PRODIGE-72 study.

Author

Hammel, Pascal, primary, Ben Abdelghani, Meher, additional, Roth, Gael, additional, Ulusakarya, Ayhan, additional, Ghiringhelli, François, additional, Toullec, Clemence, additional, Borg, Christophe, additional, Hentic Dhome, Olivia, additional, Trouilloud, Isabelle, additional, Dahan, Laetitia, additional, Hiret, Sandrine, additional, Bouche, Olivier, additional, Rinaldi, Yves, additional, Blanc, Jean-Frédéric, additional, De La Fouchardiere, Christelle, additional, Neuzillet, Cindy, additional, Kamal, Maud, additional, Falcoz, Antoine, additional, Turpin, Anthony, additional, and Guimbaud, Rosine, additional

Published
2024
Full Text
View/download PDF

8. Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial

Author

Gallois, Claire, Emile, Jean-François, Kim, Stefano, Monterymard, Carole, Gilabert, Marine, Bez, Jérémie, Lièvre, Astrid, Dahan, Laetitia, Laurent-Puig, Pierre, Mineur, Laurent, Coriat, Romain, Legoux, Jean-Louis, Hautefeuille, Vincent, Phelip, Jean-Marc, Lecomte, Thierry, Sokol, Harry, Capron, Claude, Randrian, Violaine, Lepage, Come, Lomenie, Nicolas, Kurtz, Camille, Taieb, Julien, and Tougeron, David

Published
2021
Full Text
View/download PDF

10. How to Balance Prognostic Factors in Controlled Phase II Trials: Stratified Permuted Block Randomization or Minimization? An Analysis of Clinical Trials in Digestive Oncology.

Author

Martin, Elodie, Le Malicot, Karine, Guérin-Charbonnel, Catherine, Bocquet, François, Bouché, Olivier, Turpin, Anthony, Aparicio, Thomas, Legoux, Jean-Louis, Dahan, Laetitia, Taieb, Julien, Lepage, Côme, Dourthe, Louis-Marie, Pétorin, Caroline, Bourgeois, Vincent, Raoul, Jean-Luc, and Seegers, Valérie

Subjects
PROGNOSIS, CLINICAL trials, ONCOLOGY, ESTIMATION bias
Abstract

In controlled phase II trials, major prognostic factors need to be well balanced between arms. The main procedures used are SPBR (Stratified Permuted Block Randomization) and minimization. First, we provide a systematic review of the treatment allocation procedure used in gastrointestinal oncology controlled phase II trials published in 2019. Second, we performed simulations using data from six phase II studies to measure the impacts of imbalances and bias on the efficacy estimations. From the 40 articles analyzed, all mentioned randomization in both the title and abstract, the median number of patients included was 109, and 77.5% were multicenter. Of the 27 studies that reported at least one stratification variable, 10 included the center as a stratification variable, 10 used minimization, 9 used SBR, and 8 were unspecified. In real data studies, the imbalance increased with the number of centers. The total and marginal imbalances were higher with SBR than with minimization, and the difference increased with the number of centers. The efficiency estimates per arm were close to the original trial estimate in both procedures. Minimization is often used in cases of numerous centers and guarantees better similarity between arms for stratification variables for total and marginal imbalances in phase II trials. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial.

Author

Tougeron, David, Dahan, Laetitia, Evesque, Ludovic, Le Malicot, Karine, El Hajbi, Farid, Aparicio, Thomas, Bouché, Olivier, Bonichon Lamichhane, Nathalie, Chibaudel, Benoist, Angelergues, Antoine, Bodere, Anaïs, Phelip, Jean-Marc, Mabro, May, Kaluzinski, Laure, Petorin, Caroline, Breysacher, Gilles, Rinaldi, Yves, Zaanan, Aziz, Smith, Denis, and Gouttebel, Marie-Claude

Published
2024
Full Text
View/download PDF

12. Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study

Author

Randrian, Violaine, Adenis, Antoine, Desrame, Jérôme, Barbier, Emilie, Di Fiore, Frédéric, Lièvre, Astrid, Dahan, Laetitia, Laurent-Puig, Pierre, Mineur, Laurent, Breysacher, Gilles, Roquin, Guillaume, Louafi, Samy, Lopez, Anthony, Louvet, Christophe, Borg, Christophe, Metges, Jean Philippe, Faroux, Roger, Gaba, Lila, Manfredi, Sylvain, and Tougeron, David

Published
2020
Full Text
View/download PDF

13. Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase I dose-escalation study with panitumumab (FFCD 0904)

Author

Vendrely, Véronique, Lemanski, Claire, Gnep, Khemara, Barbier, Emilie, Hajbi, Farid El, Lledo, Gerard, Dahan, Laëtitia, Terrebonne, Eric, Manfredi, Sylvain, Mirabel, Xavier, Mammar, Vincent, Cowen, Didier, Lepage, Come, and Aparicio, Thomas

Published
2019
Full Text
View/download PDF

14. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC)

Author

Neuzillet, Cindy, Gaujoux, Sébastien, Williet, Nicolas, Bachet, Jean-Baptiste, Bauguion, Lucile, Colson Durand, Laurianne, Conroy, Thierry, Dahan, Laetitia, Gilabert, Marine, Huguet, Florence, Marthey, Lysiane, Meilleroux, Julie, de Mestier, Louis, Napoléon, Bertrand, Portales, Fabienne, Sa Cunha, Antonio, Schwarz, Lilian, Taieb, Julien, Chibaudel, Benoist, Bouché, Olivier, and Hammel, Pascal

Published
2018
Full Text
View/download PDF

15. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

Author

Harding, James J, primary, Fan, Jia, additional, Oh, Do-Youn, additional, Choi, Hye Jin, additional, Kim, Jin Won, additional, Chang, Heung-Moon, additional, Bao, Lequn, additional, Sun, Hui-Chuan, additional, Macarulla, Teresa, additional, Xie, Feng, additional, Metges, Jean-Phillippe, additional, Ying, Jie'er, additional, Bridgewater, John, additional, Lee, Myung-Ah, additional, Tejani, Mohamedtaki A, additional, Chen, Emerson Y, additional, Kim, Dong Uk, additional, Wasan, Harpreet, additional, Ducreux, Michel, additional, Bao, Yuanyuan, additional, Boyken, Lisa, additional, Ma, Jiafang, additional, Garfin, Phillip, additional, Pant, Shubham, additional, Abou-Alfa, Ghassan, additional, Alfonso, Jorge Adeva, additional, Aglietta, Massimo, additional, Baron, Ari, additional, Beg, Muhammad, additional, Aguirre, Paula Carrasco, additional, Chen, Eric, additional, Cheng, Ying, additional, Gracián, Antonio Cubillo, additional, Dahan, Laetitia, additional, De Braud, Filippo, additional, Fenocchio, Elisabetta, additional, Gbolohon, Olumide, additional, Gillmore, Roopinder, additional, Jary, Marine, additional, Javle, Milind, additional, Jiang, Yixing, additional, Kang, Jung Hun, additional, King, Gentry George, additional, Kundranda, Madappa, additional, Layos, Laura, additional, Li, Daneng, additional, Liang, Tingbo, additional, Lonardi, Sara, additional, Marathe, Omkar, additional, Mondaca, Sebastian, additional, Martin, Andrés J. Muñoz, additional, Park, Joon Oh, additional, Pazo Cid, Roberto, additional, Fernandez, Paula Ribera, additional, Rimassa, Lorenza, additional, Alonso, Rosa Rodriguez, additional, Sadeghi, Saeed, additional, Scott, Aaron, additional, Tan, Benjamin, additional, Tougeron, David, additional, Yan, Qiang, additional, Yin, Xiaoyu, additional, and Zhao, Haitao, additional

Published
2023
Full Text
View/download PDF

18. Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41–BEVANEC randomized phase II study

Author

Walter, Thomas, Malka, David, Hentic, Olivia, Lombard-Bohas, Catherine, Le Malicot, Karine, Smith, Denis, Ferru, Aurélie, Assenat, Eric, Cadiot, Guillaume, Lievre, Astrid, Kurtz, Jean-Emmanuel, Dahan, Laetitia, Dubreuil, Olivier, Hautefeuille, Vincent, Lepere, Céline, Gangloff, Alice, Elhajbi, Farid, Coriat, Romain, Roquin, Guillaume, Bouarioua, Nadia, Granger, Victoire, Scoazec, Jean-Yves, and Lepage, Côme

Published
2018
Full Text
View/download PDF

19. Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours

Author

Lepage, Côme, Dahan, Laetitia, Bouarioua, Nadia, Toumpanakis, Christos, Legoux, Jean-Louis, Le Malicot, Karine, Guimbaud, Rosine, Smith, Denis, Tougeron, David, Lievre, Astrid, Cadiot, Guillaume, Di Fiore, Frédéric, Bouhier-Leporrier, Karine, Hentic, Olivia, Faroux, Roger, Pavel, Marianne, Borbath, Ivan, Valle, Juan W., Rinke, Anja, Scoazec, Jean-Yves, Ducreux, Michel, and Walter, Thomas

Published
2017
Full Text
View/download PDF

20. Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial

Author

Walter, Thomas, primary, Lievre, Astrid, additional, Coriat, Romain, additional, Malka, David, additional, Elhajbi, Farid, additional, Di Fiore, Fréderic, additional, Hentic, Olivia, additional, Smith, Denis, additional, Hautefeuille, Vincent, additional, Roquin, Guillaume, additional, Perrier, Marine, additional, Dahan, Laetitia, additional, Granger, Victoire, additional, Sobhani, Iradj, additional, Mineur, Laurent, additional, Niccoli, Patricia, additional, Assenat, Eric, additional, Scoazec, Jean-Yves, additional, Le Malicot, Karine, additional, Lepage, Côme, additional, and Lombard-Bohas, Catherine, additional

Published
2023
Full Text
View/download PDF

21. Trimodality therapy with carboplatin/paclitaxel (CP) or FOLFOX (FFX) for esophageal/esogastric junctional cancer (EC/EGJ): Expanded safety and efficacy data from PROTECT.

Author

Adenis, Antoine, primary, Piessen, Guillaume, additional, Le Sourd, Samuel, additional, Bogart, Emilie, additional, Paumier, Amaury, additional, Vendrely, Veronique, additional, Glehen, Olivier, additional, Dahan, Laetitia, additional, Simmet, Victor, additional, Bergeat, Damien, additional, Samalin, Emmanuelle, additional, Chauvenet, Marion, additional, d'Journo, Xavier Benoit, additional, Hiret, Sandrine, additional, Gronnier, Caroline, additional, Baty, Manon, additional, Pannier, Diane, additional, Veziant, Julie, additional, Le Deley, Marie-Cecile, additional, and Mirabel, Xavier, additional

Published
2023
Full Text
View/download PDF

22. Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer

Author

Strickler, John H., primary, Satake, Hironaga, additional, George, Thomas J., additional, Yaeger, Rona, additional, Hollebecque, Antoine, additional, Garrido-Laguna, Ignacio, additional, Schuler, Martin, additional, Burns, Timothy F., additional, Coveler, Andrew L., additional, Falchook, Gerald S., additional, Vincent, Mark, additional, Sunakawa, Yu, additional, Dahan, Laetitia, additional, Bajor, David, additional, Rha, Sun-Young, additional, Lemech, Charlotte, additional, Juric, Dejan, additional, Rehn, Marko, additional, Ngarmchamnanrith, Gataree, additional, Jafarinasabian, Pegah, additional, Tran, Qui, additional, and Hong, David S., additional

Published
2023
Full Text
View/download PDF

23. Carcinoembryonic antigen kinetics predict response to first-line treatment in metastatic colorectal cancer: Analysis from PRODIGE 9 trial

Author

Salfati, Delphine, primary, Huot, Margaux, additional, Aparicio, Thomas, additional, Lepage, Come, additional, Taieb, Julien, additional, Bouché, Olivier, additional, Boige, Valérie, additional, Phelip, Jean-Marc, additional, Dahan, Laetitia, additional, Bennouna, Jaafar, additional, Le Malicot, Karine, additional, Boussari, Olayide, additional, and Gornet, Jean-Marc, additional

Published
2023
Full Text
View/download PDF

25. Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?

Author

Passot, Guillaume, Kim, Bradford J., Glehen, Olivier, Mehran, Reza J., Kopetz, Scott E., Goere, Diane, Overman, Michael J., Pocard, Marc, Marchal, Frédéric, Conrad, Claudius, Aloia, Thomas A., Vauthey, Jean-Nicolas, Chun, Yun Shin, Abba, Julio, Abboud, Karine, Alyami, Mohammad, Arvieux, Catherine, Asnacios, Amani, Averous, Gerlinde, Bakrin, Naoual, Bardier, Armelle, Rejeb, Houda Ben, Bereder, Jean-Marc, Bernard, Jean-Louis, Bibeau, Frédéric, Bonnefoy, Isabelle, Borg, Christophe, Boschetti, Gilles, Bouarioua, Nadia, Bouche, Olivier, Bouzard, Dominique, Brigand, Cécile, Cacheux, Wulfran, Capitain, Olivier, Carrère, Sébastien, Carretier, Michel, Castel, Benjamin, Chauvenet, Marion, Chevallier, Anne, Coffin, Benoît, Costan, Cristina, Cotte, Eddy, Courvoisier, Thomas, Dahan, Laetitia, Dartigues, Peggy, De Chaisemartin, Cécile, Dechelotte, Pierre, Deguelte-Lardière, Sophie, Delpero, Jean-Robert, Del Grande, Jean, Demarchi, Martin, Desandes, Emmanuel, Desolneux, Grégoire, Dufour, Patrick, Dumont, Frédéric, Durand-Fontanier, Sylvaine, Eveno, Clarisse, Evrard, Serge, Facy, Olivier, Farkhondeh, Fereshteh, Fontaine, Juliette, Gagniere, Johan, Galais, Marie-Pierre, Ghouti, Laurent, Gilly, François-Noël, Goasguen, Nicolas, Gornet, Jean-Marc, Gourdiole, Pierre, Guerin-Meyer, Véronique, Guilloit, Jean-Marc, Guimbaud, Rosine, Guyon, Frédéric, Heyd, Bruno, Heymann, Marie-Françoise, Isaac, Sylvie, Jouet, Pauline, Jourdan-Enfer, Peggy, Jouve, Jean-Louis, Kaci, Rachid, Karoui, Mehdi, Kianmanesh, Reza, Kirzin, Sylvain, Kurtz, Jean-Emmanuel, Labrousse, François, Lebrun-Ly, Valérie, Lefevre, Jérémie, Lelong, Bernard, Lemaistre, Anne-Elisabeth, Leroux-Broussier, Agnès, Levillain, Pierre, Linot, Benjamin, Dico, Réa Lo, Loi, Valéria, Lorimier, Gérard, Mahammat, Abakar, Malka, David, Marchal, Frédéric, Mariani, Antoine, Mariani, Pascale, Mariette, Christophe, Martin, Laurent, Meeus, Pierre, Meffert, Jean-Luc, Messager, Mathieu, Michel, Pierre, Msika, Simon, Muron, Thierry, Noel, Georges, Ortega-Deballon, Pablo, Paquette, Brice, Peoc’h, Michel, Petorin, Caroline, Peyrat, Patrice, Pezet, Denis, Piessen, Guillaume, Pirro, Nicolas, Pocard, Marc, Poizat, Flora, Porcheron, Jack, Poulet, Anaïs, Portales, Fabienne, la Denise, Justine Prost a, Quenet, François, Rat, Patrick, Rebischung, Christine, Regimbeau, Jean-Marc, Rivoirard, Romain, Rohr, Serge, Rougier, Philippe, Rousselot, Pierre, Saban-Roche, Léa, Sabate, Jean-Marc, Sabbagh, Charles, Sabourin, Jean-Christophe, Samalin-Scalzi, Emmanuelle, Seitz, Jean-François, Selves, Janick, Senellart, Helène, Serrano, Martine, Sgabura, Olivia, Sielezneff, Igor, Svrcek, Magali, Taibi, Abdelkader, Taieb, Julien, Thibaudeau, Emilie, Tougeron, David, Tuech, Jean-Jacques, Valmary-Degano, Séverine, Vaudoyer, Delphine, Verriele-Beurrier, Véronique, Villeneuve, Laurent, Volet, Julien, Wernert, Romuald, Ychou, Marc, You, Benoît, Zaanan, Aziz, Zinzindohoue, Franck, and on behalf of the BIG-RENAPE Working Group

Published
2017
Full Text
View/download PDF

28. Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial – Prodige 31 REMINET: An FFCD study

Author

Lepage, Côme, primary, Phelip, Jean-Marc, additional, Lievre, Astrid, additional, Le-Malicot, Karine, additional, Dahan, Laetitia, additional, Tougeron, David, additional, Toumpanakis, Christos, additional, Di-Fiore, Frédéric, additional, Lombard-Bohas, Catherine, additional, Borbath, Ivan, additional, Coriat, Romain, additional, Lecomte, Thierry, additional, Guimbaud, Rosine, additional, Petorin, Caroline, additional, Legoux, Jean-Louis, additional, Michel, Pierre, additional, Scoazec, Jean-Yves, additional, Smith, Denis, additional, and Walter, Thomas, additional

Published
2022
Full Text
View/download PDF

29. Associations between the severity of medical and surgical complications and perception of surgeon empathy in esophageal and gastric cancer patients

Author

Gehenne, Lucie, Lelorain, Sophie, Eveno, Clarisse, Piessen, Guillaume, Mariette, Christophe, Glehen, Olivier, d'Journo, Xavier, Mathonnet, Muriel, Regenet, Nicolas, Meunier, Bernard, Baudry, Anne-Sophie, Christophe, Véronique, Adenis, Antoine, Aparicio, Thomas, Assenat, Eric, Barret, Maximilien, Benhaim, Leonor, Benoit, Céline, Bergeat, Damien, Boige, Valérie, Borie, Fréderic, Bouche, Olivier, Bourriez, Damien, Brichon, Pierre-Yves, Brigand, Cécile, Carrere, Nicolas, Cattan, Pierre, Christou, Niki, Coffin, Benoit, Cohen, Romain, Collet, Denis, Conroy, Thierry, Dahan, Laetitia, Deguelte, Sophie, Di Fiore, Fréderic, Dousset, Bertrand, Drouillard, Antoine, Dumont, Frédéric, Elhajbi, Farid, Fabre, Jean Michel, Fabre, Joseph, Gagniere, Johan, Galais, Marie Pierre, Germain, Adeline, Geyl, Sophie, Goere, Diane, Gornet, Jean Marc, Granger, Victoire, Gronnier, Caroline, Guimbaud, Rosine, Hautefeuille, Vincent, Helyon, Morgane, Jougon, Jacques, Lebreton, Gilles, Lefevre, Jérémie, Lepage, Côme, Lievre, Astrid, Marchal, Frédéric, Mathieu, Pierre, Mathysiak, Tamara, Michot, Nicolas, Moszkowicz, David, Moussata, Driffa, Msika, Simon, Neuzillet, Cindy, Ouaissi, Medhi, Paquette, Brice, Paye, François, Penna, Christophe, Père, Guillaume, Perrier, Marine, Peschaud, Frédérique, Pezet, Denis, Phoutthsang, Valérie, Pocard, Marc, Rat, Paul, Regimbeau, Jean Marc, Renaud, Florence, Sabate, Jean-Marc, Souche, Régis, Terrebonne, Eric, Tessier, Williams, Thomas, Pascal Alexandre, Turpin, Anthony, Vaudoyer, Delphine, Vienot, Angélique, Voron, Thibault, You, Benoit, Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 (SCALab), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 (CANTHER), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de Chirurgie digestive, endocrinienne et générale [CHU Limoges], CHU Limoges, Centre hospitalier universitaire de Nantes (CHU Nantes), CHU Pontchaillou [Rennes], Centre hospitalier [Valenciennes, Nord], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut de Génétique Moléculaire de Montpellier (IGMM), and Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
medicine.medical_specialty, Esophageal Neoplasms, media_common.quotation_subject, education, [SDV.CAN]Life Sciences [q-bio]/Cancer, Empathy, MESH: Perception, Odds, Postoperative complications, MESH: Surgeons, 03 medical and health sciences, 0302 clinical medicine, Stomach Neoplasms, Perception, Internal medicine, Humans, Medicine, 030212 general & internal medicine, Major complication, Retrospective Studies, Cancer, media_common, Multinomial logistic regression, Surgeons, Physician-Patient Relations, MESH: Humans, business.industry, Nursing research, MESH: Retrospective Studies, Cognition, MESH: Stomach Neoplasms, medicine.disease, Patient-physician communication, MESH: Empathy, Oncology, 030220 oncology & carcinogenesis, MESH: Esophageal Neoplasms, MESH: Physician-Patient Relations, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; Objective: To assess the impact of global physician empathy and its three subdimensions (establishing rapport, emotional and cognitive processes) on the severity of postoperative complications in a sample of cancer patients.Methods: We retrospectively analyzed data on 256 patients with esogastric cancer from the French national FREGAT database. Empathy and its subdimensions were assessed using the patient-reported CARE scale and the severity of medical and surgical complications was reported with the Clavien-Dindo classification system. The usual covariates were included in multinomial logistic regression analyses.Results: Physician empathy predicted the odds of reporting major complications. When patients perceived high empathy, they were less likely to report major complications compared to no complications (OR = .95, 95% CI = [.91-.99], p = .029). Among the three dimensions, only "establishing rapport" (OR = .84, 95% CI = [.73-.98], p = .019) and the "emotional process" (OR = .85, 95% CI = [.74-.98], p = .022) predicted major complications.Conclusions: Physician empathy is essential before surgery. Further research is needed to understand the mechanisms associating empathy with health outcomes in cancer. Physicians should be trained to establish good rapport with patients, especially in the preoperative period.

Published
2021

30. Preoperative chemoradiation (CRT) with carboplatin (CBP)/paclitaxel (PCL) (CP) or with 5-fluorouracil (FU)/oxaliplatin (OX) (Fx) for esophageal or junctional cancer: A randomized phase 2 trial.

Author

Adenis, Antoine, primary, Le Sourd, Samuel, additional, Mirabel, Xavier, additional, Paumier, Amaury, additional, Bogart, Emilie, additional, Vendrely, Veronique, additional, Glehen, Olivier, additional, Dahan, Laetitia, additional, Simmet, Victor, additional, Bergeat, Damien, additional, Samalin, Emmanuelle, additional, Chauvenet, Marion, additional, d'Journo, Xavier Benoit, additional, Hiret, Sandrine, additional, Gronnier, Caroline, additional, Gnep, Khémara, additional, Vanseymortier, Marie, additional, El Hajbi, Farid, additional, Le Deley, Marie-Cecile, additional, and Piessen, Guillaume, additional

Published
2022
Full Text
View/download PDF

31. The PRODIGE 59-DURIGAST trial: A randomized phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-esophageal junction adenocarcinoma.

Author

Tougeron, David, primary, Dahan, Laetitia, additional, El Hajbi, Farid, additional, Le Malicot, Karine, additional, Evesque, Ludovic, additional, Aparicio, Thomas, additional, Bouché, Olivier, additional, Bonichon-Lamichhane, Nathalie, additional, Chibaudel, Benoist, additional, Angelergues, Antoine, additional, Bordere, Anais, additional, Phelip, Jean-Marc, additional, Mabro, May, additional, Artru, Pascal, additional, and Louvet, Christophe, additional

Published
2022
Full Text
View/download PDF

32. Durvalumab (D) plus tremelimumab (T) immunotherapy in patients (Pts) with advanced biliary tract carcinoma (BTC) after failure of platinum-based chemotherapy (CTx): Interim results of the IMMUNOBIL GERCOR D18-1 PRODIGE-57 study.

Author

Delaye, Matthieu, primary, Assenat, Eric, additional, Dahan, Laetitia, additional, Blanc, Jean-Frédéric, additional, Tougeron, David, additional, Metges, Jean-Philippe, additional, Lievre, Astrid, additional, Turpin, Anthony, additional, Fares, Nadim, additional, De La Fouchardiere, Christelle, additional, Castanie, Hélène, additional, Desrame, Jérôme, additional, Pellat, Anna, additional, Lecomte, Thierry, additional, Bignon, Anne Laure, additional, Hautefeuille, Vincent, additional, Garcia-Larnicol, Marie-Line, additional, Falcoz, Antoine, additional, Ben Abdelghani, Meher, additional, and Neuzillet, Cindy, additional

Published
2022
Full Text
View/download PDF

33. sj-docx-2-tam-10.1177_17588359221141307 – Supplemental material for Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial

Author

de Rauglaudre, Bernadette, Sibertin-Blanc, Camille, Fabre, Aurélie, Le Malicot, Karine, Bennouna, Jaafar, Ghiringhelli, François, Taïeb, Julien, Boige, Valérie, Bouché, Olivier, Chatellier, Thierry, Faroux, Roger, François, Eric, Jacquot, Stéphane, Genet, Dominique, Mulot, Claire, Olschwang, Sylviane, Seitz, Jean-François, Aparicio, Thomas, and Dahan, Laetitia

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-2-tam-10.1177_17588359221141307 for Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial by Bernadette de Rauglaudre, Camille Sibertin-Blanc, Aurélie Fabre, Karine Le Malicot, Jaafar Bennouna, François Ghiringhelli, Julien Taïeb, Valérie Boige, Olivier Bouché, Thierry Chatellier, Roger Faroux, Eric François, Stéphane Jacquot, Dominique Genet, Claire Mulot, Sylviane Olschwang, Jean-François Seitz, Thomas Aparicio and Laetitia Dahan in Therapeutic Advances in Medical Oncology

Published
2022
Full Text
View/download PDF

34. sj-docx-1-tam-10.1177_17588359221141307 – Supplemental material for Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial

Author

de Rauglaudre, Bernadette, Sibertin-Blanc, Camille, Fabre, Aurélie, Le Malicot, Karine, Bennouna, Jaafar, Ghiringhelli, François, Taïeb, Julien, Boige, Valérie, Bouché, Olivier, Chatellier, Thierry, Faroux, Roger, François, Eric, Jacquot, Stéphane, Genet, Dominique, Mulot, Claire, Olschwang, Sylviane, Seitz, Jean-François, Aparicio, Thomas, and Dahan, Laetitia

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tam-10.1177_17588359221141307 for Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial by Bernadette de Rauglaudre, Camille Sibertin-Blanc, Aurélie Fabre, Karine Le Malicot, Jaafar Bennouna, François Ghiringhelli, Julien Taïeb, Valérie Boige, Olivier Bouché, Thierry Chatellier, Roger Faroux, Eric François, Stéphane Jacquot, Dominique Genet, Claire Mulot, Sylviane Olschwang, Jean-François Seitz, Thomas Aparicio and Laetitia Dahan in Therapeutic Advances in Medical Oncology

Published
2022
Full Text
View/download PDF

35. Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation

Author

Wang, Judy, primary, Martin-Romano, Patricia, additional, Cassier, Philippe, additional, Johnson, Melissa, additional, Haura, Eric, additional, Lenox, Laurie, additional, Guo, Yue, additional, Bandyopadhyay, Nibedita, additional, Russell, Michael, additional, Shearin, Elizabeth, additional, Lauring, Josh, additional, and Dahan, Laetitia, additional

Published
2022
Full Text
View/download PDF

36. Clinical Impact of High Throughput Sequencing on Liquid Biopsy in Advanced Solid Cancer

Author

Gouton, Etienne, primary, Malissen, Nausicaa, additional, André, Nicolas, additional, Jeanson, Arnaud, additional, Pelletier, Annick, additional, Testot-Ferry, Albane, additional, Gaudy-Marqueste, Caroline, additional, Dahan, Laetitia, additional, Tabouret, Emeline, additional, Chevalier, Thomas, additional, Greillier, Laurent, additional, and Tomasini, Pascale, additional

Published
2022
Full Text
View/download PDF

37. Ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma: INTERACTION phase II study.

Author

Kim, Stefano Chong Hun, primary, Boustani, Jihane, additional, Vernerey, Dewi, additional, Vendrely, Veronique, additional, FRANCOIS, Eric, additional, Quero, Laurent, additional, Ghiringhelli, Francois, additional, De La Fouchardiere, Christelle, additional, Dahan, Laetitia, additional, Bouché, Olivier, additional, Chibaudel, Benoist, additional, El Hajbi, Farid, additional, Vernet, Chloé, additional, Rebucci-Peixoto, Magali, additional, Espinal-Dominguez, Edward, additional, MARITAZ, Christophe, additional, and Borg, Christophe, additional

Published
2022
Full Text
View/download PDF

38. Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial

Author

de Rauglaudre, Bernadette, primary, Sibertin-Blanc, Camille, additional, Fabre, Aurélie, additional, Le Malicot, Karine, additional, Bennouna, Jaafar, additional, Ghiringhelli, François, additional, Taïeb, Julien, additional, Boige, Valérie, additional, Bouché, Olivier, additional, Chatellier, Thierry, additional, Faroux, Roger, additional, François, Eric, additional, Jacquot, Stéphane, additional, Genet, Dominique, additional, Mulot, Claire, additional, Olschwang, Sylviane, additional, Seitz, Jean-François, additional, Aparicio, Thomas, additional, and Dahan, Laetitia, additional

Published
2022
Full Text
View/download PDF

39. Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials

Author

Pietrasz, Daniel, primary, Wang-Renault, Shufang, additional, Taieb, Julien, additional, Dahan, Laetitia, additional, Postel, Mathilde, additional, Durand-Labrunie, Jerome, additional, Le Malicot, Karine, additional, Mulot, Claire, additional, Rinaldi, Yves, additional, Phelip, Jean-Marc, additional, Doat, Solene, additional, Blons, Hélène, additional, de Reynies, Aurelien, additional, Bachet, Jean-Baptiste, additional, Taly, Valérie, additional, and Laurent-Puig, Pierre, additional

Published
2021
Full Text
View/download PDF

40. Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort

Author

Pernot, Simon, Mitry, Emmanuel, Samalin, Emmanuelle, Dahan, Laetitia, Dalban, Cécile, Ychou, Marc, Seitz, Jean-François, Turki, Hajer, Mazard, Thibault, Zaanan, Aziz, Lepère, Céline, Vaillant, Jean-Nicolas, Landi, Bruno, Rougier, Philippe, and Taieb, Julien

Published
2014
Full Text
View/download PDF

43. Renal function in patients receiving streptozocin for locally advanced or metastatic digestive neuroendocrine tumours: results of the Streptotox-FFCD 0906 study

Author

Legoux, Jean-Louis, primary, Lombard-Bohas, Catherine, additional, Brixi, Hedia, additional, Le Malicot, Karine, additional, Lecomte, Thierry, additional, Dahan, Laetitia, additional, Ruszniewski, Philippe, additional, Mahamat-Abakar, Abakar, additional, Etienne, Pierre-Luc, additional, Caroli-Bosc, François-Xavier, additional, Dominguez, Sophie, additional, Paule, Bernard, additional, Terrebonne, Eric, additional, Michel, Pierre, additional, Lepage, Côme, additional, and Choukroun, Gabriel, additional

Published
2021
Full Text
View/download PDF

45. Second-Line Chemotherapy for Advanced Biliary Tract Cancer After Failure of the Gemcitabine-Platinum Combination: A Large Multicenter Study by the Association des Gastro-EntéRologues Oncologues

Author

Brieau, Bertrand, Dahan, Laetitia, De Rycke, Yann, Boussaha, Tarek, Vasseur, Philippe, Tougeron, David, Lecomte, Thierry, Coriat, Romain, Bachet, Jean-Baptiste, Claudez, Pierre, Zaanan, Aziz, Soibinet, Pauline, Desrame, Jérome, Thirot-Bidault, Anne, Trouilloud, Isabelle, Mary, Florence, Marthey, Lysiane, Taieb, Julien, Cacheux, Wulfran, and Lièvre, Astrid

Published
2015
Full Text
View/download PDF

47. Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma.

Author

Canton, Clémence, Boussari, Olayidé, Boulin, Mathieu, Malicot, Karine Le, Taieb, Julien, Dahan, Laetitia, Lopez, Anthony, Lepage, Come, and Bachet, Jean-Baptiste

Subjects
PANCREATIC tumors, ADENOCARCINOMA, GRANULOCYTE-colony stimulating factor, CONFIDENCE intervals, CANCER chemotherapy, ANTINEOPLASTIC agents, METASTASIS, NEUTROPENIA, RETROSPECTIVE studies, CANCER patients, KAPLAN-Meier estimator, DESCRIPTIVE statistics, DRUG side effects, ODDS ratio, CHEMOPREVENTION, PROPORTIONAL hazards models
Abstract

Background In metastatic pancreatic adenocarcinoma, few data are available on the use of granulocyte-colony stimulating factor (G-CSF) prophylaxis and its impact on dose-intensity (DI), or the link between DI and progression-free survival (PFS). This study assessed the impact of G-CSF prophylaxis on the DI received by patients and the relationship between full DI and PFS according to chemotherapy regimens. Patients and Methods Patients from three first-line randomized phase II clinical trials were included in this retrospective cohort. G-CSF prophylaxis groups were identified and balanced according to baseline characteristics using a propensity score. Patients were classified into 2 treatment groups (FOLFIRINOX vs FOLFIRI/nab-paclitaxel (NAB)). DI was a binary variable (full/reduced). Adverse events were defined using NCI-CTCAE v4.0. Results Of the 498 patients, 154 (31%) were in "prophylaxis" group; 179 (36%) were treated by FOLFIRINOX and 319 (64%) by FOLFIRI/NAB. In FOLFIRINOX group, G-CSF prophylaxis was significantly associated with a higher rate of full DI (OR, 5.07; 95% CI, 1.52-16.90; P <.01) while in FOLFIRI/NAB group, it was significantly associated with a lower rate of full DI (OR, 0.23; 95% CI, 0.06-0.83; P =.03). Full DI was associated with a non-significant increase in PFS (FOLFIRINOX group: HR 0.83; 95% CI, 0.59-1.16; P =.27; FOLFIRI/NAB group: HR 0.84; 95% CI, 0.63-1.11; P =.22). Conclusion Granulocyte-colony stimulating factor prophylaxis was associated with a higher rate of full DI with FOLFIRINOX. Full DI was associated with a non-significant increase in PFS. These results need to be confirmed prospectively. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

48. DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity

Author

Yang, Chen Guang, Ciccolini, Joseph, Blesius, Aurore, Dahan, Laetitia, Bagarry-Liegey, Danielle, Brunet, Caroline, Varoquaux, Arthur, Frances, Nicolas, Marouani, Hafedh, Giovanni, Antoine, Ferri-Dessens, Rose-Marie, Chefrour, Mohamed, Favre, Roger, Duffaud, Florence, Seitz, Jean-François, Zanaret, Michel, Lacarelle, Bruno, and Mercier, Cédric

Published
2011
Full Text
View/download PDF

49. Paper: combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)

Author

Dahan, Laetitia, Bonnetain, Frank, Ychou, Marc, Mitry, Emmanuel, Gasmi, Mohamed, Raoul, Jean-Luc, Cattan, Stephane, Phelip, Jean-Marc, Hammel, Pascal, Chauffert, Bruno, Michel, Pierre, Legoux, Jean-Louis, Rougier, Philippe, Bedenne, Laurent, and Seitz, Jean-Francois

Subjects
Pancreatic cancer -- Drug therapy, Pancreatic cancer -- Patient outcomes, Metastasis -- Drug therapy, Metastasis -- Patient outcomes, Drug therapy, Combination -- Usage, Drug therapy, Combination -- Patient outcomes, Health
Published
2010

Catalog

Books, media, physical & digital resources
See catalog results